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Helicobacter hepaticus is a murine micro-
aerophilic bacterium ﬁrst noted in association
with unexplained cases of hepatitis and liver
tumors in our animal colony (Ward et al.
1994b) and subsequently isolated and charac-
terized as a new species (Fox et al. 1994).
Koch’s postulates were fulﬁlled with regard to
causation of persistent chronic hepatitis (Fox
et al. 1996b). H. hepaticus selectively colonizes
the hepatic bile canaliculi of mice, causing a
morphologically distinctive pattern of chronic
active progressive hepatitis, and also persis-
tently infects the large bowel. H. hepaticus
infection is readily established in mice by intra-
gastric (ig) or intraperitoneal (ip) treatment
with bacterial suspensions, and this method is
commonly used to study the disease.
In our initial study of A/J male mice natu-
rally infected with H. hepaticus, we observed
hepatitis of increasing severity with age, with
most mice exhibiting hepatitis by 1 year (Rice
1995; Ward et al. 1994a). Liver tumors
occurred in 6% of the mice at 1 year of age, in
50% at 15 months, and in 92% at 18 months.
This high incidence of liver tumorigenesis was
striking, in view of human gastric cancer and
lymphoma associated with infection by
Helicobacter pylori. A later study with another
sample of the naturally infected A/J males gave
similar quantitative results, with liver tumors
in 40% of the males at 12–15 months of age
(Diwan et al. 1997). Similarly, another labora-
tory reported liver tumors in 75% of naturally
infected A/J males at 15–18 months of age
(Fox et al. 1996a). Thus, the model seemed
promising as an experimental system for study
of bacterial carcinogenesis.
However, studies with experimental infec-
tion by injection of cultured bacteria have
yielded lower liver tumor incidences. In an
investigation involving ig treatment of mice
with H. hepaticus at 10 weeks of age, and
including both sexes and a selection of recom-
binant inbred strains, liver preneoplasia/neopla-
sia incidence at 14 months of age was, at most,
20% (Ihrig et al. 1999). Avenaud et al. (2003)
exposed A/J mice at 3–4 weeks of age to a rela-
tively low titer of H. hepaticus (107) ig and
examined small groups of mice at ages up to
17 months. Although all mice tested positive
for the bacterium, hepatitis was relatively mild,
and no liver tumors were observed. Possible
insight into the reason for the low yield of liver
tumors in these studies was offered by Rogers
et al. (2004), who exposed A/J mice to
H. hepaticus at various perinatal stages and at
12 weeks of age and evaluated the livers at time
points up to 12 months of age. Although the
limited numbers of mice in each group con-
strained statistical certainty, the results sug-
gested that exposure before 12 weeks of age was
required for development of hepatitis and liver
dysplasia: none of the four male mice treated at
12 weeks had these lesions, whereas such
changes occurred in 30–70% of those exposed
by treatment of the dams at conception or on
fetal day 10, or of offspring at 3 weeks of age.
We therefore tested whether progressive
hepatitis and a high incidence of liver tumors
with aging requires perinatal exposure, as
would occur in naturally infected mouse
colonies. Our ﬁnding that such is, in fact, the
case may have bearing on the potential impor-
tance of human perinatal exposure to infec-
tious agents on later health consequences. A
preliminary report of this work has appeared
in abstract form (Diwan et al. 2001).
Materials and Methods
H. hepaticus culturing, treatment, and detec-
tion. We used H. hepaticus, Frederick strain 1A
(passage 7), which was isolated contemporane-
ously from the same colony of mice as those
providing the tissues used for cloning and
genetic analysis of the bacterium and deposi-
tion in the American Type Culture Collection
(Fox et al. 1994, 1996b). We grew the bacteria
under microaerophilic conditions at 37°C on
plates of Brucella agar with horse blood and
trimethoprim, vancomycin, and polymyxin B
(TVP) (Remel Co., Lenexa, KS) for 3 days.
This bacterial strain has subsequently been
shown to be detected by H. hepaticus–speciﬁc
polymerase chain reaction (PCR) primers and
to be negative for all PCR-based tests for all
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BACKGROUND: Although severe hepatitis and liver tumors occur in a high percentage of A/J male
mice naturally infected with Helicobacter hepaticus, these effects have not been observed after injec-
tion of adult mice with the bacteria.
OBJECTIVES: We tested the hypothesis that perinatal exposure to the bacteria is required for liver
tumorigenesis.
METHODS: A/J female mice were infected by intragastric (ig) or intraperitoneal (ip) treatment with
1.5 × 108 H. hepaticus before pregnancy. We examined offspring at progressive time intervals,
including some kept until natural death in old age. A/J, BALB/c, and C57BL/6 weanling male mice
were similarly treated ig with the bacteria and observed for up to 2 years.
RESULTS: After ip bacterial infection of A/J females, 41% of their male offspring developed hepatitis
and 33% had hepatocellular tumors, including 18% with hepatocellular carcinoma. Treatment by
the ig route resulted in a similar incidence of hepatitis in offspring (35%) but fewer total liver
tumors (8%) and carcinomas (4%). By contrast, ig instillation of H. hepaticus in weanling A/J,
C57BL/6, or BALB/c mice resulted in low incidence of hepatitis (0–20%) and few liver tumors,
despite presence of bacteria conﬁrmed in feces.
CONCLUSIONS: Results indicate that a high incidence of liver tumors in mice infected with
H. hepaticus requires perinatal exposure. Contributing perinatal factors could include known high
sensitivity of neonatal liver to tumor initiation, and/or modulation of immune response to the bac-
terium or its toxins. Mechanisms of human perinatal sensitivity to such phenomena can be studied
with this model.
KEY WORDS: adult exposure, Helicobacter hepaticus, hepatocellular tumors, infection and cancer,
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able via http://dx.doi.org/ [Online 13 June 2008]other Helicobacter species. To check for motility
and morphology, the organism was harvested,
suspended in brain heart infusion broth with
horse serum and yeast extract (Remel Co.), and
visualized by phase-contrast microscopy. 
For the in vivo studies, the organism was
harvested and suspended in sterile phosphate-
buffered saline (PBS), and the concentration
was adjusted to a McFarland equivalence tur-
bidity standard of 1.0 (3 × 108 bacteria/mL).
We tested viability of the suspended organisms
by phase-contrast microscopy to determine
motility and by subculturing onto Brucella
blood agar plates with TVP as described above,
both before and after animal inoculations. 
All mice were obtained from the Animal
Production Area at NCI Frederick. The
National Cancer Institute (NCI)-Frederick is
accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care
International and follows the U.S. Public
Health Service policy for the care and use of
laboratory animals. We provided animal care in
accordance with the procedures as outlined by
the Institute of Laboratory Animal Resources
(1996). Animals were treated humanely and
with regard for alleviation of suffering. Animal
treatments consisted of a single dose of
1.5 × 108 bacteria in 0.5 mL PBS. 
Treated mice were maintained in semi-rigid
isolators (Charles River, Boston, MA), and con-
trols were housed in rooms free of the bacteria.
Mice were kept in polycarbonate cages with cel-
lulose ﬁber chips as bedding. We assayed feces
samples for the presence of Helicobacter spp. by
passing the samples through a 0.45-µm ﬁlter
and then streaking them onto Brucella agar
with horse blood and TVP at 37°C under
microaerophilic conditions. We compared
appearance of growth of these cultures with
that of starting cultures of H. hepaticus. 
Perinatal exposure by maternal injection
with H. hepaticus. We used uninfected male
and female A/JCr (A/J) mice for this study. We
injected 4-week-old females ip or ig with
0.5 mL bacterial suspension. Feces samples
from these mice were checked for presence of
the bacteria after 3 weeks, and females positive
for fecal bacteria were bred with uninfected
males. We allowed some females to produce
more than one litter. Male offspring were
weaned and euthanized when moribund or at
18 or 24 months of age. Mothers were kept
until euthanized because of morbidity. Female
offspring were not retained because H. hepati-
cus–associated liver tumorigenesis has been
observed mainly in male mice.
Perinatal exposure by maternal and neona-
tal exposure to H. hepaticus through feces. Six
cages containing 2-year-old A/J males with feces
positive for H. hepaticus were available (one to
three per cage). At the start, we removed the
males from a cage that they had occupied for
4 days and transferred the soiled bedding to
cages housing pregnant females (one or two
such cages for each cage of males). Litters were
born an average of 7 days after initial exposure
to soiled bedding. This H. hepaticus exposure
procedure was repeated daily, 5 days/week,
until pups were weaned. We weaned 32 male
offspring from nine litters and maintained them
until moribund; remaining mice were eutha-
nized at 24 months of age. We monitored feces
from their cages periodically for the presence of
H. hepaticus, collecting a total of eight samples
over time from each cage. 
Six of the male offspring from cages with
positive tests for fecal Helicobacter were bred to
uninfected females in order to test their capa-
bility for infection of subsequent generations.
We obtained a total of 18 male F2 offspring. 
Experimental infection of weanling mice.
Uninfected A/J males were treated at 3–4 weeks
of age with H. hepaticus suspension ig or with
PBS only. Mice exposed to the bacteria were
maintained in isolators. At 2, 4, 12, 24, and
54 weeks after treatment, fecal samples
were cultured to determine the presence of
H. hepaticus, and mice from each group were
euthanized as indicated in Table 1. Mice that
died naturally or were moribund during the
course of the study were included for analysis
with the end point group closest in time. A
small number of mice were allowed to live until
natural morbidity; their average ages are given
in Table 1. We collected livers from all animals
up to 54 weeks and divided them into lobes; we
either froze portions of each lobe in liquid
nitrogen or ﬁxed them in 10% neutral buffered
formalin for histopathologic analysis. We ana-
lyzed two lobes each from randomly selected
livers, representing each time point and group,
to determine levels of 8-hydroxydeoxyguano-
sine (8-oxo-dG), a marker for oxidative DNA
damage, in liver DNA as previously described
(Sipowicz et al. 1997). Results for mice at 2, 4,
and 12 weeks after exposure have been pub-
lished previously (Sipowicz et al. 1997). 
To test the effect of different genetic back-
grounds, we performed a second experiment
with male weanling mice of the BALB/cAnNCr
(BALB/c), C57BL/6NCr (C57BL/6), and A/J
strains. Small groups of mice were euthanized at
3, 6, and 12 months of age, and the remainder
were maintained until morbidity or natural
death. Fecal samples were monitored periodi-
cally for Helicobacter.
Histopathology. We subjected all mice to
complete necropsy and fixed tissues in 10%
neutral formalin. Liver, stomach, and ceca, as
well as any abnormal masses or lesions, were
examined for each mouse. We evaluated sever-
ity of pathologic changes in livers semi-
quantitatively on a scale of 1 to 4 (minimal,
mild, moderate, or severe), and diagnosed typ-
ical H. hepaticus–associated hepatitis (chronic
active hepatitis) on the basis of simultaneous
presence of the following lesions: mild to
severe multifocal necrosis, subacute inﬂamma-
tion, inﬁltration of peribiliary leukocytes, bile
ductule hyperplasia, oval cell hyperplasia,
hepatocytomegaly, and lymphocytic infiltra-
tion (Rice 1995; Ward et al. 1994a, 1994b).
We also noted minimal foci of subacute
inflammation and lymphocytic infiltrates,
which are common liver lesions in normal
mice of many strains, but they were not asso-
ciated with Helicobacter infection and are thus
not included here. Steiner’s silver stain was
used for histologic confirmation of the pres-
ence of helical bacteria in liver sections.
Statistical analysis. We analyzed data using
GraphPad InStat, version 3.00 (GraphPad
Software, San Diego, CA). Tests included a
t-test for parametric data and Mann-Whitney
or Kruskal-Wallis tests for nonparametric data
as appropriate.
Results
Liver tumorigenesis in male A/J offspring after
maternal exposure to H. hepaticus. Females
treated with H. hepaticus suspensions ip and
Perinatal H. hepaticus and liver tumors
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Table 1. Hepatic and cecal lesions and hepatic oxidative DNA damage in A/J mice exposed ig as wean-
lings to H. hepaticus and in controls.
Weeks after Tumors Chronic active Oxidative DNA damagea Cecal proliferative typhlitis
exposure Group No. [n (%)] hepatitis [n (%)] No.b 8-Oxo-dG/105 dG ± SE [No. (%), severity scorec]
2 Exp 15 0 0 3 (6) 1.3 ± 0.1* 1 (7), 1.0 
Con 15 0 0 3 (4) 0.8 ± 0.1 0
4 Exp 15 0 0 3 (6) 1.3 ± 0.1** 2 (13), 1.0 ± 0
Con 16 0 0 2 (4) 0.8 ± 0.03 1 (7), 1.0
12 Exp 15 0 2 (13) 3 (6) 2.1 ± 0.2** 6 (40)*, 1.7 ± 0.2
Con 16 0 0 3 (5) 1.2 ± 0.1 1 (6), 1.0
24 Exp 10 0 1 (10) 5 (9) 2.3 ± 0.1** 7 (70)**, 1.6 ± 0.3
Con 10 0 0 5 (10) 1.5 ± 0.1 0
36 Exp 15 0 0 4 (7) 2.1 ± 0.3 8 (53)**, 1.6 ± 0.2
Con 16 0 0 4 (8) 2.0 ± 0.2 1 (6), 1.0
54 Exp 5 0 1 (20) 5 (10) 2.3 ± 0.3 2 (40), 2.0 ± 0
Con 5 0 0 5 (10) 2.0 ± 0.1 0
> 54d Exp 6 1 (17) 0 ND 0
Con 4 1 (25) 0 ND 0
Abbreviations: Con, untreated controls; Exp, experimentally infected with H. hepaticus; ND, not done
aResults for weeks 2–12 were reported previously by Sipowicz et al. (1997). bNumber of livers analyzed (total number of
samples). cMean ± SE. dMean (± SE) ages of experimental and control mice were 743 ± 48 and 623 ± 68 days, respectively. 
*p < 0.05, and **p < 0.01, compared with control mice at the same time point.found to have positive fecal cultures were
mated. Four females produced a total of
27 male offspring, which were housed in
groups of two to four. All cages gave positive
results for H. hepaticus in feces, and the num-
ber of mice per cage had no obvious relation-
ship to outcomes (data not shown). At an
average age of about 22 months, 11 (41%) of
these male offspring had Helicobacter hepatitis.
Of these, 9 (33%) had at least one liver tumor,
7 (26%) had multiple tumors, and 5 (18%)
had hepatocellular carcinoma (Table 2).
Hepatocholangiolar tumors, an adenoma and a
carcinoma, occurred in 2 mice. We found
tumors in offspring of each of the mothers. All
of the hepatocellular tumors occurred in livers
that also had Helicobacter hepatitis, which was
moderate to severe in all cases except for one,
which was categorized as mild. Three livers
that did not have a tumor had minimal or mild
chronic active hepatitis. The four mothers were
euthanized when moribund at 49–87 weeks of
age; of the four livers, three had chronic
inflammation of moderate intensity, but no
hepatitis characteristic of Helicobacter infection. 
Female mice treated ig with the same
H. hepaticus preparations as the ip-treated
females and found to have positive fecal cul-
tures were bred. Five mothers produced a total
of 26 male offspring. Fecal cultures from both
the mothers and the male offspring were posi-
tive for Helicobacter. Among these male off-
spring, 35% had Helicobacter hepatitis, an
incidence similar to that in male offspring of
the ip-treated females (Table 2). However,
despite greater average age of these mice, the
average severity of the hepatitis was less (close
to significance). Only two mice (8%) had
hepatocellular tumors, and no mouse had mul-
tiple liver tumors. These values are signiﬁcantly
different from those in the male offspring of
ip-treated females. The ﬁve ig-treated mothers
were euthanized at 67–105 weeks of age. We
did not observe chronic inﬂammation of the
liver (p = 0.048 compared with chronic inﬂam-
mation in three of four ip-treated mothers). 
To test the efﬁcacy of bacterial transmission
through feces, we exposed pregnant mice and
their offspring up to the time of weaning to
feces from Helicobacter-positive male mice.
Eight litters yielded a total of 32 male offspring.
Incidence of males with Helicobacter hepatitis
(19%) was less than that in offspring of moth-
ers exposed ip (41%), but this difference was
only of borderline signiﬁcance (p = 0.086), and
average severity grade was similar (Table 2). We
observed only one liver tumor, a hepatocellular
carcinoma in a male of advanced age without
hepatitis. Feces from four of the nine cages
housing these mice were positive for H. hepati-
cus at approximately monthly samplings
between 1 month and 1 year of age.
We further tested fecal transmission by
mating Helicobacter-positive male offspring
from the above study with uninfected
females. We obtained a total of 20 male off-
spring from nine litters. Although these F2
mice were terminated at earlier ages than mice
in the other studies, the incidence and average
grade of Helicobacter hepatitis were very simi-
lar to those for the F1 males exposed directly
to contaminated feces during gestation and
infancy (Table 2). We found no liver tumors
in the F2 males. 
We noted typhlitis and hyperplasia of gut-
associated lymphoid tissue (GALT) in 4–19%
of the male offspring in the various perinatal
exposure groups, with no significant differ-
ences among them.
Lack of tumorigenic effectiveness of ig
treatment of A/J weanling mice with
H. hepaticus. We tested H. hepaticus of the
same strain used for the perinatal studies above
in weanling A/J mice. Chronic active hepatitis
associated with experimental ig H. hepaticus
infection was ﬁrst apparent after 12 weeks after
exposure and occurred with low frequency at
later time points, but never exceeding 20%
(Table 1). We noted mild-to-moderate
histopathologic changes (scores of 2–3) in 6 of
15 (40%) of the livers of experimentally
infected mice at 12 weeks after exposure but
none in the controls (p = 0.0068). Subacute
inﬂammation was the most common hepatic
lesion (5 of 15) in these mice. The incidence of
this change decreased at 24 weeks (1 of 10)
and 36 weeks (1 of 15) after exposure. We
observed mild-to-moderate peribiliary leuko-
cyte infiltration in a small percentage of the
exposed mice at ≥ 12 weeks after exposure, but
in none of the controls through 54 weeks
(4 of 45 vs. 0 of 47, p = 0.053). Similarly,
mild-to-moderate necrosis occurred only in the
exposed mice (9 of 81 vs. 0 of 82, p = 0.0015).
Thus, we observed apparent hepatic effects
of the H. hepaticus infection in some of the
mice, but these were not striking, and typical
Helicobacter-associated hepatitis was rare.
Correspondingly, only two mice, one exposed
and one control, presented with liver tumors at
advanced ages. The control tumor, at 751 days
of age, was a hepatocellular adenoma. An
exposed mouse at 790 days of age presented
four hepatocellular adenomas, one hepato-
cholangiolar adenoma, and a hemangio-
sarcoma within the liver; however, hepatitis
typical of H. hepaticus was not present.
We measured levels of 8-oxo-dG indica-
tive of oxidative DNA damage in two to ﬁve
randomly selected mice for each treatment cat-
egory and time point up to 1 year; in most
cases, samples from the median and left liver
lobes were analyzed for each mouse. As shown
in Table 1, a significant increase in hepatic
8-oxo-dG had already occurred within
2 weeks of infection. We obtained very similar
results at 4 weeks. We noted a further increase
at 12 weeks after exposure, where the elevated
level of 8-oxo-dG was highly signiﬁcant com-
pared with controls at this age and compared
with exposed mice at 4 weeks. Thereafter, the
level of 8-oxo-dG in the livers of the infected
mice did not change significantly, whereas
that in the controls increased steadily, as is
expected with aging. The difference relative to
the controls was still significant at 24 weeks
after exposure, but not at 36 or 54 weeks.
8-oxo-dG levels were not clearly correlated
with histopathologic findings: At 24 weeks
postexposure, the average number of
8-oxo-dG residues in hepatic DNA from the
mouse with clear Helicobacter hepatitis was
2.27/105 dG residues, compared with
2.28/105 dG in one without liver lesions. At
54 weeks after exposure, the liver with hepati-
tis had 1.67 8-oxo-dG residues per 105 dG,
whereas one with minimal hepatic change had
1.74 residues/105 dG. However, because of
the focal nature of the hepatitis, lack of corre-
spondence with 8-oxo-dG levels cannot be
concluded with certainty.
Fecal samples taken from cages of experi-
mentally infected mice at 2–24 weeks after
exposure were positive for H. hepaticus. No
samples were taken at 36 weeks. For the three
cages of mice at 54 weeks after exposure, two
Diwan et al.
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Table 2. Histopathologic ﬁndings in A/J mice exposed to H. hepaticus perinatally and in controls [n (%)].
Mothers Mothers Mothers and newborns F2 offspring of
Characteristic exposed ip exposed ig exposed through feces feces-exposed males
No. 27 26 32 20
Average age (days) 674 ± 18 674 ± 28 647 ± 22 458 ± 16
Helicobacter hepatitis positive 11 (41) 9 (35) 6 (19) 5 (25)
Average grade 3.0 ± 0.4* 2.0 ± 0.3* 2.5 ± 0.2 2.6 ± 0.6
Average age (days) 669 ± 20 713 ± 18 675 ± 62 441 ± 40
Hepatocellular tumors present 9a (33)**, #  2 (8)** 1 (3)# 0
Multiple hepatocellular tumorsb 7 (26)##,†  0## 0† 0
Hepatocellular carcinoma 5 (18) 1 (4) 1 (3) 0
Typhlitis 1 (4) 3 (12) 3 (9) 1 (5)
Hyperplasia of GALT 1 (4) 3 (12) 6 (19) 3 (15)
Values shown are mean ± SE or number (%) except where indicated.
aEight had hepatocellular tumors (three with adenomas only, ﬁve with adenoma and carcinoma, one each with hepato-
cellular adenoma and carcinoma and either cholangioma or cholangiocarcinoma), and one had cholangioma only. The
liver with hepatocholangiolar adenoma was the only liver with tumor that did not have Helicobacter hepatitis.bMultiplicity
could not be quantified because of extensive tumor involvement throughout many of the livers. Significance of differ-
ences between values with matched superscripts: *p = 0.07, **p = 0.039, #p = 0.0035, ##p = 0.01, †p = 0.0026. cages were positive and one was negative. No
bacterial growth occurred for the control fecal
samples at any time point.
With regard to the gastrointestinal tract,
we found hyperplasia of the glandular stomach
in 17 of 81 (21%) exposed mice and in 11 of
82 (13%) controls, not a signiﬁcant difference
(p = 0.22). Histopathologic examination of
ceca revealed hyperplasia of GALT in 7–40%
of mice, with no signiﬁcant differences in inci-
dence between exposed and control mice.
Proliferative typhlitis occurred predominately
in the exposed mice (Table 1); incidence was
highest at 12–54 weeks after exposure and was
significantly greater than controls at 12, 24,
and 36 weeks, with an apparent decrease
thereafter. The incidence in all exposed mice
at 12–36 weeks (21 of 40) was significantly
greater than the incidence at > 54 weeks
(0 of 6; p = 0.025).
Conﬁrmation of lack of tumorigenic effec-
tiveness of experimental infection with
H. hepaticus in A/J, BALB/c, and C57BL/6 as
weanlings. To conﬁrm the results noted above
for A/J mice and to test whether other mouse
strains might be more susceptible, we repeated
the experiment and included BALB/c and
C57BL/6 mice (Table 3). Small subsets of
mice were euthanized at interim time points
and all mice remaining at 1 year of age were
maintained until natural morbidity. Fecal sam-
ples throughout the course of the study con-
firmed the presence of helical bacteria shed
from all of the treated mice and from none of
the controls. We observed few age-dependent
differences. A summary of lesions for all mice
in the study is presented in Table 3.
We diagnosed chronic active hepatitis rarely
in two exposed BALB/c mice and one exposed
C57BL/6 mouse (Table 3). Liver tumors
occurred in low incidence in old mice and were
not signiﬁcantly different in treated versus con-
trol groups. Among the experimentally infected
mice presenting H. hepaticus–associated hepati-
tis, we found one hepatocellular carcinoma in a
BALB/c mouse at 778 days of age, and three
adenomas in a C57BL/6 mouse at 720 days.
Several histopathologic changes were sig-
niﬁcantly associated with treatment in at least
one of the mouse strains. We found hyperpla-
sia of the nonglandular stomach in 6 of
30 (20%) infected A/J mice, compared with
0 of 29 controls (p = 0.024). Five of the cases
were in old mice, and four were moderate or
severe. In the other strains, gastric hyperplasia
was uncommon and not associated with treat-
ment. Table 3 shows other signiﬁcant altera-
tions. In A/J mice, proliferative typhlitis was
more common in ceca of infected versus con-
trol mice at all end points, and these differ-
ences were significant for all mice combined
(Table 3). However, the incidence of prolifera-
tive typhlitis was reduced to 7% in infected A/J
mice at 2 years of age. Signiﬁcant differences in
these parameters were also observed for
BALB/c mice; in this strain, frequency of
hyperplasia of GALT was also higher in the
mice infected with H. hepaticus: 15 of
23 (65%) versus 9 of 33 (27%) (p = 0.0066).
Fecal samples confirmed that all three
strains of experimentally infected mice, but
no controls, were shedding H. hepaticus at all
time points.
Discussion
The results of this study conﬁrm the ﬁndings
of other investigations (Avenaud et al. 2003;
Ihrig et al. 1999); we found that ig injection of
weanling or young adult A/J mice with
H. hepaticus reliably leads to early hepatic
changes—in 40% of the mice in our study at
12 weeks after exposure—as well as marked
increases in oxidative DNA damage, but liver
tumors are rarely an outcome. With increasing
time after exposure, fecal samples became less
uniformly positive, a lower proportion of livers
exhibited Helicobacter-related damage, and the
elevated oxidative DNA damage relative to
controls disappeared. We discovered few
hepatitis-related tumors or preneoplastic foci,
none in A/J mice. These results are in contrast
to those reported for naturally infected mice;
for example, Sipowicz et al. (1997) measured a
steady increase in 8-oxo-dG at 10, 12, and
18 months of age. Such mice had high
incidence (92%) of liver tumors at 18 months
of age (Ward et al. 1994b). Together, the
results are consistent with host immune
response successfully suppressing H. hepaticus
in mice infected after weaning.
In the A/J and BALB/c mouse strains,
infection with H. hepaticus resulted in several
hepatic and cecal changes, including prolifera-
tive typhlitis, as observed in other studies. We
observed no effects in C57BL/6 mice, con-
ﬁrming the resistance of this strain to hepatic
effects of the bacteria (Ihrig et al. 1999; Ward
et al. 1994a, 1994b), despite the greater con-
centration of bacteria in the ceca of C57BL/6
than in A/J mice (Whary et al. 2001).
In contrast, perinatal infection of A/J mice
by ip injection of their mothers with
H. hepaticus before breeding led to a high
incidence of progressive hepatitis and signiﬁ-
cant numbers of multiple liver tumors, includ-
ing hepatocellular carcinomas, in their male
offspring. This conﬁrms the previous ﬁnding
of Rogers et al. (2004). The present study par-
tially reproduces the high incidence of liver
tumors in naturally infected A/J males and
provides an experimental paradigm for gener-
ating H. hepaticus–associated liver tumors. We
observed lesser effects in male offspring of
mothers treated with H. hepaticus ig before
conception. Intragastric treatment might be
expected to be less effective for establishing a
systemic infection with H. hepaticus than ip
treatment. We conﬁrmed this by the presence
of chronic inflammation in the livers of ip-
treated mothers but not ig-treated mothers. In
a study with H. pylori and a novel Helicobacter
species, McCathey et al. (1999) found that
ip-administered bacteria, but not ig adminis-
tration at the same titer, resulted in hepatitis
and elicited a much greater immune response.
Thus, the likelihood of transmission of pro-
gressive disease to offspring may be a function
of degree of infection of the mother, and the
very high incidences of hepatitis and tumors
in male offspring of naturally infected moth-
ers, seen in our original population of infected
mice, may reﬂect the level of bacterial burden
accumulated over generations. However, the
possibility of attenuation of bacterial virulence
with serial passaging cannot be ruled out
at present.
The bacteria might pass from mother to
offspring transplacentally, through milk, or
through feces. Li et al. (1998) were able to
culture H. hepaticus from about 20% of fetal
viscera in severe combined immunodeﬁciency
(SCID) mice, but not from any of 14 A/J
fetuses. This indicates that transplacental
transmission is at least possible. However,
Singletary et al. (2003) eliminated mother-to-
pup transmission of H. hepaticus for C57BL/6
females experimentally infected ig with this
bacterium by foster nursing the newborns
within 24 hr after birth. Thus, under these
conditions, at least, transmission was not
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Table 3. Summary of lesions in livers and ceca of mice of different strains experimentally infected as
weanlings with H. hepaticus and in controls.
Liver Proliferative
Strain Group No. Hepatitis tumor typhlitis
A/J Infected 30 0 0 11 (37)*
Control 29 0 1a 3 (10)
BALB/c Infected 23 2 (9) 1 (4)b 7 (30)*
Control 33 0 3 (9)c 1 (3)
C57BL/6 Infected 33 1 (3) 6 (18)d 1 (3)
Control 28 0 8 (29)e 3 (11)
Values shown are number (%).
aHepatocellular adenoma, mouse 462 days of age. bHepatocellular adenoma, mouse 778 days of age, grade 2 hepatitis;
also eosinophilic foci. cTwo hepatocellular adenomas in mice 637 and 683 days of age, and one carcinoma in mouse 610
days of age; all without hepatitis.d Three mice with single adenomas, one mouse with three adenomas and hepatitis (neg-
ative for presence of Helicobacter with Steiner’s stain), and one mouse each with hepatoblastoma or with hepatocholan-
giocarcinoma. eFour mice with single hepatic adenoma, two mice each with two adenomas, and two mice each with an
adenoma and a carcinoma. *p < 0.05 compared with control mice of that strain.Diwan et al.
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transplacental. In the present study, establish-
ment of the infection by exposure to feces
from infected males, although resulting in
hepatitis in some mice, did not lead to
tumors, but maternal feces might be more
effective. Passage of bacteria in the milk is
theoretically possible.
The mechanism of hepatic tumorigenesis
after perinatal exposure may well involve
immune tolerance. In genetically engineered
mice heterozygous for the Apc gene (ApcMin/+)
and deﬁcient in lymphocytes because of lack of
Rag2, H. hepaticus infection increased both
colon and mammary tumor incidence
(Erdman et al. 2003; Rao et al. 2006a, 2006b).
This tumorigenic effect was suppressed by
CD4+CD45RBloCD25+ regulatory T cells,
especially if these were obtained from
H. hepaticus–infected mice. Such regulatory
T cells have a role in establishing tolerance to
self-antigens, which evolves during the neona-
tal period (e.g., Arnold et al. 2005). One
hypothesis is that H. hepaticus or a bacterial
product present during the neonatal period
becomes identified as “self” and so escapes
effective immune surveillance. An interesting
feature in the perinatal models we used in our
experiments was that hepatitis occurred to sim-
ilar degrees with all four modes of infection,
but hepatic tumor outcomes were quite differ-
ent. Thus, tumorigenesis involves something
more than hepatitis. H. hepaticus expresses a
cytolethal distending toxin (CDT) (Chien
et al. 2000), which is essential for colonization
of the intestines of normal mice (Ge et al.
2005), as well as for severe typhlocolitis in
immunodeficient mice (Young et al. 2004).
CDT suppresses host immune response to the
bacteria (Pratt et al. 2006); both T cells and
antigen-presenting cells may be affected. Of
particular interest in the present context, when
Ge et al. (2007) exposed A/J mice to a high
titer of bacteria, both wild-type and CDT
mutant H. hepaticus resulted in comparable
degrees of hepatitis at 4 and 10 months of age,
but only mice infected with the wild-type bac-
teria showed hepatic preneoplastic foci. A
number of proinﬂammatory mediators, includ-
ing tumor necrosis factor-α, interleukin-6, and
transforming growth factor-α, were reduced in
the absence of CDT.
These results confirm that hepatitis and
tumorigenesis are separable, and link CDT
speciﬁcally to the tumor development process
through its effects on immune system balance.
It may be that immune response to CDT
speciﬁcally is suppressed during the acquisition
of immune tolerance in the neonatal period,
resulting in higher levels of CDT production, a
qualitatively and/or quantitatively enhanced
proinflammatory, protumorigenic environ-
ment, and ultimately liver tumor development.
Chronic inﬂammatory events have long been
associated with the promotion phase of liver
tumorigenesis in rodents. Promotion of liver
tumors by H. hepaticus infection has been
demonstrated (Diwan et al. 1997).
Furthermore, the CDT also causes DNA
damage by its DNase activity (Avenaud et al.
2004) and thus could contribute to tumor ini-
tiation. It is possible that this property of CDT
explains the special sensitivity of perinates,
because liver tumors are initiated by geno-
toxicants with higher efficiency in neonatal
than in adult rodents (reviewed by Anderson
et al. 2000). In this scenario, chronic hepatitis
from H. hepaticus might lead to liver tumors
effectively only when these have been initiated
perinatally. These hypotheses may be readily
tested with the model that we have estab-
lished. In view of the enhanced virulence of
infectious agents encountered in early life in
humans, with regard to hepatic cancer caused
by hepatitis viruses (Stuver 1998), and gastric
cancers related to H. pylori (Blaser et al. 1995)
and possibly to Epstein-Barr virus (Abdirad
et al. 2007), pursuit of these mechanisms
is important.
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